Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA’s SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD).In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.BofA Securities raised the price target for Teva to $25 from $23 wit ...

Teva Pharmaceutical Industries Ltd. (TEVA) shares rallied 26.5% in the last trading session to close at $20.88. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.1% gain over the past four weeks.This jump in share price came after management reported positive results from a mid-stage study on its experimental anti-TL1A therapy, duvakitug, in Ulcerative Colitis and Crohn's disease, which are the two main types ...

Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanof ...

Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmace ...

Core Insights - Teva Pharmaceutical Industries Ltd. has entered into an agreement with JKI Co., Ltd. for the divestment of its Teva-Takeda business venture in Japan, aligning with its Pivot to Growth strategy [1][2] - The divestment will enable Teva to concentrate on its innovative medicines in the Japanese market, enhancing its focus on bringing new products to this region [1][2] - The transaction is expected to be completed by April 1, 2025, pending standard closing conditions and regulatory approvals [3] Company Strategy - The divestment is part of Teva's broader Pivot to Growth strategy, which aims to streamline operations and focus on high-quality, innovative medicines [4] - Mark Sabag, Executive Vice President, emphasized the importance of this agreement in ensuring the delivery of affordable medicines to patients in Japan [4] Operational Details - All employees of the Teva-Takeda business venture in Japan will remain employed under the terms of the agreement, ensuring continuity in operations [3] - Teva has a global workforce of approximately 37,000 employees and operates in 58 markets, highlighting its extensive reach and commitment to health improvement [4]

AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed Full data presented as a late breaker at European Headache Congress (EHC) 4-7 December in Rotterdam, Netherlands TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industr ...

Teva Pharmaceutical Industries Limited’s (TEVA) stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well as sales. The company also slightly raised its earnings and sales guidance. The stock probably declined as investors were not impressed with the guidance increase. However, some analysts believe the stock’s decline after the results was an overreaction.Teva is the world’s largest generic drug company in terms of b ...

Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials. Health insurance companies, Congress, and patients love generics. It’s a growth industry in the medical sector as drug patents generally expire after 20 years after they are filed. The Trump administration is expected to streamline the U.S. Food and Drug Administration (FDA), whi ...

Teva Pharmaceutical Industries Limited Conference Call Summary Company Overview - **Company**: Teva Pharmaceutical Industries Limited (NYSE: TEVA) - **Event**: Jefferies London Healthcare Conference - **Date**: November 19, 2024 - **Participants**: Richard Francis (President & CEO), Glen Santangelo (Jefferies Analyst) Key Points Company Strategy and Growth - Teva has experienced **seven consecutive quarters of growth**, reversing a six-year decline [6][9] - The company implemented the **Pivots Growth strategy** two years ago, focusing on four pillars: growth engine delivery, step-up innovation, generics powerhouse, and capital focus [7][10] - The growth has been driven by products such as **AUSTEDO**, **UZEDY**, and **AJOVY** [10][12] Financial Performance - Teva's stock price has shown **spectacular performance** over the last 12 months [6] - AUSTEDO is projected to reach **$2.5 billion in sales by 2027**, with current forecasts indicating **$1.6 billion** for this year [13] - The generics business grew at **70% in the U.S.**, **8% in Europe**, and **14% in Emerging Markets** [16] - Innovative products like AUSTEDO and AJOVY have seen growth rates of **28%** and **21%** respectively [17][18] Market Positioning - Teva is transitioning from a **generics powerhouse** to a more **innovative branded company** [14] - The company aims to shed the perception of being solely a generics company, emphasizing its innovative capabilities [19] Pipeline and Future Products - Teva's pipeline includes promising products such as **TL1A**, **ICS/SABA**, and **Emrusolmin** for various indications [66][67] - The **TL1A** product is expected to have a full readout by the end of the year, with plans to move into Phase III next year [48][52] - **Olanzapine** is anticipated to leverage the experience gained from UZEDY's launch, enhancing market understanding and execution [38] Challenges and Opportunities - The generics business, while performing well, faces challenges from **Revlimid** headwinds in Q4 due to contract nature [70] - Teva's **biosimilars** strategy is seen as a significant growth opportunity, with launches for **Humira** and **Stelara** expected to contribute positively [71][72] - The company is focused on improving manufacturing efficiency and supply chain management to enhance performance [26] Financial Outlook - Teva aims for a **5% CAGR**, **30% operating margin**, and **80% cash conversion** by 2027, with a target of reducing net debt to **2x net debt to EBITDA** [78] - The company is optimistic about growth in 2025, driven by a strong pipeline and generics performance [76][77] Investor Sentiment - Despite a strong Q3 performance, there was some volatility in stock price, attributed to high expectations and market conditions [55][60] - Teva's management remains focused on long-term value creation rather than short-term stock fluctuations [61][62] Conclusion Teva Pharmaceutical Industries Limited is on a positive trajectory with a clear growth strategy, strong financial performance, and a robust pipeline of innovative products. The company is well-positioned to capitalize on both its generics and branded pharmaceuticals, aiming to enhance its market perception and deliver sustained value to investors.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Jefferies London Healthcare Conference November 19, 2024 3:30 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Good morning, everyone. Thanks for joining us. For those of you who don't know me, I'm Glen Santangelo. I'm the Spec Pharm Analyst at Jefferies, and cover Teva amongst some other things. And we're very excited to be hosting, Teva, and to my right, the CEO of the Co ...